Tevogen Inc.

TVGN Nasdaq SEC CIK 1860871
Follow Tevogen Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$7M −22.3% vs same quarter last year
EPS, diluted −$1.76 −17.3% vs same quarter last year
Operating cash flow −$2M +46.4% vs same quarter last year
Operating income −$6.9M −20.5% vs same quarter last year
Net income by quarter
−$9.4M
−$10.4M
−$5.5M
−$5.7M
−$4.7M
−$5.4M
−$5.8M
−$7M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income5 fiscal years
−$80M−$60M−$40M−$20M$0$20MFY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$26.3M
FY24−$13.7M
FY23−$60.5M
FY22$4.4M
FY21-